Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · IEX Real-Time Price · USD
8.43
-0.18 (-2.09%)
At close: Jul 2, 2024, 4:00 PM
8.48
+0.05 (0.59%)
After-hours: Jul 2, 2024, 6:44 PM EDT

Inovio Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 1997
Revenue
0.8310.261.777.414.11
Upgrade
Revenue Growth (YoY)
-91.89%478.23%-76.05%80.24%-86.51%
Upgrade
Gross Profit
0.8310.261.777.414.11
Upgrade
Selling, General & Admin
47.5890.1953.7537.2527.2
Upgrade
Research & Development
86.68187.65249.2494.2588.02
Upgrade
Other Operating Expenses
10.510000
Upgrade
Operating Expenses
144.77277.84302.99131.49115.22
Upgrade
Operating Income
-143.94-267.57-301.22-124.08-111.11
Upgrade
Interest Expense / Income
1.221.251.948.77.95
Upgrade
Other Expense / Income
-10.0510.990.533.630.56
Upgrade
Pretax Income
-135.12-279.82-303.66-166.41-119.62
Upgrade
Income Tax
0000-0.26
Upgrade
Net Income
-135.12-279.82-303.66-166.41-119.36
Upgrade
Shares Outstanding (Basic)
222017138
Upgrade
Shares Outstanding (Diluted)
222017138
Upgrade
Shares Change
11.51%14.27%34.62%57.14%6.68%
Upgrade
EPS (Basic)
-6.09-14.07-17.45-12.84-14.52
Upgrade
EPS (Diluted)
-6.09-14.07-17.45-12.84-14.52
Upgrade
Free Cash Flow
-118.47-217.18-216.94-179.5-98.84
Upgrade
Free Cash Flow Per Share
-5.34-10.92-12.47-13.88-12.02
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-17300.28%-2607.35%-16972.34%-1674.25%-2702.10%
Upgrade
Profit Margin
-16239.87%-2726.67%-17109.87%-2245.39%-2902.75%
Upgrade
Free Cash Flow Margin
-14238.67%-2116.34%-12223.61%-2422.00%-2403.69%
Upgrade
EBITDA
-130.39-273.07-296.99-153.08-106.15
Upgrade
EBITDA Margin
-15671.81%-2660.89%-16734.20%-2065.53%-2581.55%
Upgrade
Depreciation & Amortization
3.55.54.734.635.52
Upgrade
EBIT
-133.89-278.56-301.72-157.71-111.67
Upgrade
EBIT Margin
-16092.90%-2714.45%-17000.76%-2127.97%-2715.71%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).